The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.
Sebastian Stintzing
Consultant or Advisory Role - Merck KGaA; Roche/Genentech
Honoraria - Bristol-Myers Squibb; Merck Serono; Roche/Genentech
Andreas Jung
Honoraria - Merck KGaA
Lisa Rossius
No relevant relationships to disclose
Dominik Paul Modest
Consultant or Advisory Role - Amgen
Honoraria - Merck Serono; Roche
Ludwig Fischer von Weikersthal
No relevant relationships to disclose
Thomas Decker
No relevant relationships to disclose
Alexander Kiani
No relevant relationships to disclose
Salah-Eddin Al-Batran
No relevant relationships to disclose
Ursula Vehling-Kaiser
No relevant relationships to disclose
Tobias Heintges
No relevant relationships to disclose
Markus Moehler
No relevant relationships to disclose
Werner Scheithauer
No relevant relationships to disclose
Thomas Kirchner
No relevant relationships to disclose
Volker Heinemann
Consultant or Advisory Role - Amgen; Merck KGaA; Roche; Sanofi
Honoraria - Amgen; Merck Serono; Roche; Sanofi